Novartis AG ADR (NVS)vsQuanterix Corp (QTRX)
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
QTRX
Quanterix Corp
$2.56
+2.40%
HEALTHCARE · Cap: $127.22M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 36855% more annual revenue ($56.69B vs $153.41M). NVS leads profitability with a 22.5% profit margin vs -80.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
QTRX
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
+81.3%
Fair Value
$31.53
Current Price
$2.56
$28.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Revenue surging 34.4% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -33.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : QTRX
The strongest argument for QTRX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 34.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : QTRX
The primary concerns for QTRX are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while QTRX is a hypergrowth play — different risk/reward profiles.
QTRX carries more volatility with a beta of 1.04 — expect wider price swings.
QTRX is growing revenue faster at 34.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 47/100), backed by strong 22.5% margins. QTRX offers better value entry with a 81.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Quanterix Corp
HEALTHCARE · MEDICAL DEVICES · USA
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advance precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the regions from Asia Pacific. The company is headquartered in Billerica, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?